Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawahara K, Danbara H
Department of Pathology, National Institute of Health, Tokyo, Japan.
Vaccine. 1994 Apr;12(5):419-26. doi: 10.1016/0264-410x(94)90118-x.
Cholera toxin B subunit (CTB) and Escherichia coli heat-labile toxin (LTB) (2 micrograms), each supplemented with a trace amount of cholera toxin (CT) (0.02-20 ng), were examined for the adjuvant effect on antibody (Ab) response against influenza inactivated HA (haemagglutinin) vaccine in Balb/c mice. Each mouse received a primary intranasal (i.n.) inoculation of the vaccine (1.5 micrograms) and the CT-containing CTB and in 4 weeks a second i.n. inoculation of the vaccine alone. The primary inoculation of the vaccine with CTB alone did not induce either anti-HA IgA or IgG Ab response, or haemagglutination-inhibition Ab responses in the serum. The vaccine with less than 2 ng of CT also failed to induce Ab response. On the other hand, the vaccine with CT-containing CTB induced a high Ab response, which increased depending on the CT dose. Moreover, the second vaccine induced a response more than ten times higher than the primary one and the response increased depending on the CT dose. Similar enhancement was found in the local anti-HA IgA Ab response in the nasal wash. Such synergistic effects were observed also between LTB and CT. The amount of Ab produced by the synergism was considered to be enough to protect against virus infection. These results suggest that CTB (or LTB) containing a trace amount of CT (about 0.1%) can be used practically as a potent adjuvant for nasal vaccination of humans against influenza.
检测霍乱毒素B亚基(CTB)和大肠杆菌不耐热毒素(LTB)(2微克),每种均补充微量霍乱毒素(CT)(0.02 - 20纳克),对Balb/c小鼠流感灭活血凝素(HA)疫苗抗体(Ab)反应的佐剂效应。每只小鼠初次经鼻(i.n.)接种疫苗(1.5微克)以及含CT的CTB,4周后再次经鼻单独接种疫苗。单独用CTB初次接种疫苗未诱导血清中抗HA IgA或IgG抗体反应,也未诱导血凝抑制抗体反应。含少于2纳克CT的疫苗也未能诱导抗体反应。另一方面,含CT的CTB疫苗诱导了高抗体反应,且该反应随CT剂量增加而增强。此外,第二次接种疫苗诱导的反应比初次接种高十多倍,且该反应随CT剂量增加而增强。在鼻腔灌洗中的局部抗HA IgA抗体反应中也发现了类似增强。在LTB和CT之间也观察到了这种协同效应。协同作用产生的抗体量被认为足以预防病毒感染。这些结果表明,含有微量CT(约0.1%)的CTB(或LTB)实际上可作为人类流感鼻内疫苗接种的有效佐剂。